Japanese pharmaceutical company Astellas Pharma is set to acquire Belgian drug discovery company Ogeda with an identical definitive agreement also signed.

"Private equity firm Apollo Capital has acquired an additional 7.5% stake in GLG Pharma, increasing its total stake in the target company to 11.33%."

The consideration for the acquisition is €500m ($532.5m) in an initial cash payment to acquire 100% equity in the target company at the closing of the agreement, and an additional €300m ($319.49m) upon attaining clinical development and regulatory milestones for a drug named fezolinetant.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The acquisition is expected to be completed in the second quarter of this year.

Private equity firm Apollo Capital has acquired an additional 7.5% stake in GLG Pharma, increasing its total stake in the target company to 11.33%.

GLG Pharma is a biotechnology company based in the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact